Study explorer (study characteristics and results) method abbreviations

display ongoing studies
Study studied treatmentcontrol treatmentpatientsrisk of biassample sizes Results

COVID 19 hospitalized meta-analysis

SOLIDARITY (interferon), 2020
 
NCT04315948
RCTinterferoncontrolCOVID 19 hospitalizedsome concern
2063/2064 inconclusive
  • inconclusive 16 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
Synairgen SG016, 2020
 
NCT04385095
RCTSNG001 inhaled interferon betaplaceboCOVID 19 hospitalizedhigh
50/51 suggested
    no demonstrated benefit a
  • suggested 1.3-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias

COVID-19 mild to moderate meta-analysis

Fu, 2020
 
ChiCTR2000030262
RCTinterferon / TFF2standard of careCOVID-19 mild to moderatesome concern
40/40 no results
    Idelsis, 2020
     
    RPCEC00000307
    RCTinterferoninterferonCOVID-19 mild to moderatehigh
    30/33 conclusif
    • demonstrated 2.3-fold increase in PCR-negative conversion (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias

    COVID-19 severe or critically meta-analysis

    Davoudi-Monfared, 2020
     
    IRCT20100228003449N2
    RCTinterferonstandard of careCOVID-19 severe or criticallyhigh
    46/46 no results
      Yekaninejad, 2020
       
      IRCT20100228003449N2
      RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
      33/33 conclusif
      • demonstrated 2.4-fold increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);